TScan Therapeutics (TCRX) Stock Forecast, Price Target & Predictions
TCRX Stock Forecast
TScan Therapeutics stock forecast is as follows: an average price target of $12.00 (represents a 109.06% upside from TCRX’s last price of $5.74) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
TCRX Price Target
The average price target for TScan Therapeutics (TCRX) is $12.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $12.00 to $12.00. This represents a potential 109.06% upside from TCRX's last price of $5.74.
TCRX Analyst Ratings
According to 2 Wall Street analysts, TScan Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for TCRX stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
TScan Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 16, 2024 | Justin Zelin | BTIG | $12.00 | $8.93 | 34.38% | 109.06% |
The latest TScan Therapeutics stock forecast, released on May 16, 2024 by Justin Zelin from BTIG, set a price target of $12.00, which represents a 34.38% increase from the stock price at the time of the forecast ($8.93), and a 109.06% increase from TCRX last price ($5.74).
TScan Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $12.00 |
| Last Closing Price | $5.74 | $5.74 | $5.74 |
| Upside/Downside | -100.00% | -100.00% | 109.06% |
In the current month, the average price target of TScan Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to TScan Therapeutics's last price of $5.74. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 13, 2024 | Wedbush | Buy | Buy | Hold |
| Aug 13, 2024 | Needham | Underperform | Underperform | Hold |
| Jun 04, 2024 | Needham | Underperform | Underperform | Hold |
| Jun 04, 2024 | Wedbush | Buy | Buy | Hold |
| May 16, 2024 | BTIG | - | Buy | Initialise |
| May 13, 2024 | Wedbush | Buy | Buy | Hold |
| May 13, 2024 | Needham | Underperform | Underperform | Hold |
TScan Therapeutics's last stock rating was published by Wedbush on Aug 13, 2024. The company gave TCRX a "Buy" rating, the same as its previous rate.
TScan Therapeutics Financial Forecast
TScan Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $7.21M | - | - | $6.80M | $1.00K | $3.36M | - | $3.02M | $2.85M | $2.41M | $2.85M |
| Avg Forecast | $1.60M | $1.60M | $1.60M | $1.60M | $1.44M | $1.17M | $1.80M | $3.98M | $3.45M | $4.45M | $4.37M | $4.87M | $4.10M | $3.93M | $3.00M | $2.76M | $3.47M | $3.48M | $3.37M |
| High Forecast | $3.77M | $3.77M | $3.77M | $3.77M | $3.39M | $2.27M | $4.25M | $9.38M | $5.40M | $10.50M | $10.32M | $11.48M | $9.66M | $9.27M | $3.00M | $3.73M | $4.69M | $4.71M | $4.56M |
| Low Forecast | $754.72K | $754.72K | $754.72K | $754.72K | $678.40K | $229.60K | $849.06K | $1.88M | $2.03M | $2.10M | $2.06M | $2.30M | $1.93M | $1.85M | $3.00M | $1.73M | $2.18M | $2.19M | $2.12M |
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | - | 2 | 2 | 2 |
| Surprise % | - | - | - | - | - | - | - | - | 2.09% | - | - | 1.40% | 0.00% | 0.86% | - | 1.10% | 0.82% | 0.69% | 0.85% |
TScan Therapeutics's average Quarter revenue forecast for Mar 24 based on 1 analysts is $3.98M, with a low forecast of $1.88M, and a high forecast of $9.38M. TCRX's average Quarter revenue forecast represents a -44.88% decrease compared to the company's last Quarter revenue of $7.21M (Dec 23).
TScan Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | - | 2 | 2 | 2 |
| EBITDA | - | - | - | - | - | - | - | - | $-20.08M | $-24.75M | $-24.61M | $-21.61M | $-17.75M | $-14.79M | - | $-16.16M | $-13.06M | $-14.78M | $-10.01M |
| Avg Forecast | $-960.00K | $-960.00K | $-960.00K | $-960.00K | $-862.92K | $-703.56K | $-1.08M | $-2.38M | $-2.07M | $-2.67M | $-2.62M | $-2.92M | $-2.46M | $-2.36M | $-1.80M | $-1.65M | $-2.08M | $-12.17M | $-7.44M |
| High Forecast | $-452.83K | $-452.83K | $-452.83K | $-452.83K | $-407.04K | $-137.76K | $-509.43K | $-1.13M | $-1.22M | $-1.26M | $-1.24M | $-1.38M | $-1.16M | $-1.11M | $-1.80M | $-1.04M | $-1.31M | $-9.74M | $-5.96M |
| Low Forecast | $-2.26M | $-2.26M | $-2.26M | $-2.26M | $-2.04M | $-1.36M | $-2.55M | $-5.63M | $-3.24M | $-6.30M | $-6.19M | $-6.89M | $-5.80M | $-5.56M | $-1.80M | $-2.24M | $-2.81M | $-14.61M | $-8.93M |
| Surprise % | - | - | - | - | - | - | - | - | 9.69% | 9.27% | 9.38% | 7.40% | 7.22% | 6.27% | - | 9.78% | 6.28% | 1.21% | 1.35% |
undefined analysts predict TCRX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than TScan Therapeutics's previous annual EBITDA (undefined) of $NaN.
TScan Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | - | 2 | 2 | 2 |
| Net Income | - | - | - | - | - | - | - | - | $-19.61M | $-23.00M | $-24.05M | $-23.34M | $-18.80M | $-15.91M | - | $-16.15M | $-14.20M | $-15.84M | $-10.67M |
| Avg Forecast | $-34.03M | $-35.16M | $-32.52M | $-32.52M | $-36.44M | $-35.73M | $-32.08M | $-29.40M | $-32.80M | $-51.34M | $-86.77M | $-78.55M | $-82.12M | $-82.35M | $-70.59M | $-66.39M | $-66.39M | $-13.04M | $-7.94M |
| High Forecast | $-10.66M | $-11.01M | $-10.18M | $-10.18M | $-11.41M | $-26.80M | $-10.05M | $-9.21M | $-28.43M | $-16.08M | $-27.18M | $-24.60M | $-25.72M | $-25.79M | $-70.59M | $-34.36M | $-34.36M | $-10.44M | $-6.35M |
| Low Forecast | $-94.12M | $-97.26M | $-89.94M | $-89.94M | $-100.79M | $-56.94M | $-88.74M | $-81.32M | $-48.11M | $-142.00M | $-240.01M | $-217.26M | $-227.15M | $-227.77M | $-70.59M | $-96.89M | $-96.89M | $-15.65M | $-9.52M |
| Surprise % | - | - | - | - | - | - | - | - | 0.60% | 0.45% | 0.28% | 0.30% | 0.23% | 0.19% | - | 0.24% | 0.21% | 1.21% | 1.34% |
TScan Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. TCRX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
TScan Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | - | 2 | 2 | 2 |
| SG&A | - | - | - | - | - | - | - | - | $4.88M | $5.89M | $6.53M | $7.77M | $6.14M | $4.91M | - | $4.49M | $4.45M | $4.05M | $2.73M |
| Avg Forecast | $3.54M | $3.54M | $3.54M | $3.54M | $3.19M | $2.60M | $3.99M | $8.81M | $7.65M | $9.86M | $9.69M | $10.79M | $9.08M | $8.71M | $6.65M | $6.10M | $7.68M | $3.33M | $2.03M |
| High Forecast | $8.36M | $8.36M | $8.36M | $8.36M | $7.51M | $5.02M | $9.41M | $20.77M | $11.97M | $23.26M | $22.86M | $25.44M | $21.41M | $20.54M | $6.65M | $8.26M | $10.39M | $4.00M | $2.43M |
| Low Forecast | $1.67M | $1.67M | $1.67M | $1.67M | $1.50M | $508.68K | $1.88M | $4.15M | $4.50M | $4.65M | $4.57M | $5.09M | $4.28M | $4.11M | $6.65M | $3.84M | $4.83M | $2.67M | $1.62M |
| Surprise % | - | - | - | - | - | - | - | - | 0.64% | 0.60% | 0.67% | 0.72% | 0.68% | 0.56% | - | 0.74% | 0.58% | 1.21% | 1.35% |
TScan Therapeutics's average Quarter SG&A projection for Mar 24 is $8.81M, based on 1 Wall Street analysts, with a range of $4.15M to $20.77M. The forecast indicates a 80.39% rise compared to TCRX last annual SG&A of $4.88M (Dec 23).
TScan Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | - | 2 | 2 | 2 |
| EPS | - | - | - | - | - | - | - | - | $-0.21 | $-0.00 | $-0.00 | $-0.96 | $-0.78 | $-0.66 | - | $-0.67 | $-0.71 | $-0.80 | $-0.45 |
| Avg Forecast | $-0.30 | $-0.31 | $-0.29 | $-0.29 | $-0.32 | $-0.32 | $-0.28 | $-0.26 | $-0.29 | $-0.45 | $-0.77 | $-0.69 | $-0.72 | $-0.73 | $-0.74 | $-0.70 | $-0.70 | $-0.60 | $-0.65 |
| High Forecast | $-0.09 | $-0.10 | $-0.09 | $-0.09 | $-0.10 | $-0.24 | $-0.09 | $-0.08 | $-0.25 | $-0.14 | $-0.24 | $-0.22 | $-0.23 | $-0.23 | $-0.74 | $-0.36 | $-0.36 | $-0.31 | $-0.33 |
| Low Forecast | $-0.83 | $-0.86 | $-0.79 | $-0.79 | $-0.89 | $-0.50 | $-0.78 | $-0.72 | $-0.42 | $-1.25 | $-2.12 | $-1.92 | $-2.00 | $-2.01 | $-0.74 | $-1.02 | $-1.02 | $-0.88 | $-0.94 |
| Surprise % | - | - | - | - | - | - | - | - | 0.73% | 0.00% | 0.00% | 1.39% | 1.08% | 0.91% | - | 0.96% | 1.01% | 1.32% | 0.70% |
According to undefined Wall Street analysts, TScan Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to TCRX previous annual EPS of $NaN (undefined).
TScan Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| CUE | Cue Biopharma | $0.59 | $5.00 | 747.46% | Buy |
| XFOR | X4 Pharmaceuticals | $0.71 | $3.67 | 416.90% | Buy |
| DRMA | Dermata Therapeutics | $1.58 | $6.00 | 279.75% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.60 | $7.00 | 169.23% | Buy |
| INZY | Inozyme Pharma | $6.00 | $14.67 | 144.50% | Buy |
| ITOS | iTeos Therapeutics | $16.70 | $38.50 | 130.54% | Buy |
| ARWR | Arrowhead Pharmaceuticals | $21.49 | $45.38 | 111.17% | Buy |
| TCRX | TScan Therapeutics | $5.74 | $12.00 | 109.06% | Buy |
| APLS | Apellis Pharmaceuticals | $37.62 | $75.81 | 101.52% | Buy |
| PRQR | ProQR Therapeutics | $1.85 | $3.63 | 96.22% | Buy |
| ANNX | Annexon | $7.20 | $14.00 | 94.44% | Buy |
| TERN | Terns Pharmaceuticals | $8.96 | $12.50 | 39.51% | Buy |
| VECT | VectivBio | $16.87 | $18.00 | 6.70% | Buy |
TCRX Forecast FAQ
Is TScan Therapeutics a good buy?
Yes, according to 2 Wall Street analysts, TScan Therapeutics (TCRX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of TCRX's total ratings.
What is TCRX's price target?
TScan Therapeutics (TCRX) average price target is $12 with a range of $12 to $12, implying a 109.06% from its last price of $5.74. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will TScan Therapeutics stock go up soon?
According to Wall Street analysts' prediction for TCRX stock, the company can go up by 109.06% (from the last price of $5.74 to the average price target of $12), up by 109.06% based on the highest stock price target, and up by 109.06% based on the lowest stock price target.
Can TScan Therapeutics stock reach $9?
TCRX's average twelve months analyst stock price target of $12 supports the claim that TScan Therapeutics can reach $9 in the near future.
What are TScan Therapeutics's analysts' financial forecasts?
TScan Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $8.39M (high $19.28M, low $3.63M), average EBITDA is $-5.031M (high $-2.179M, low $-11.568M), average net income is $-134M (high $-57.467M, low $-328M), average SG&A $18.58M (high $42.71M, low $8.05M), and average EPS is $-1.178 (high $-0.507, low $-2.89). TCRX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $6.4M (high $15.09M, low $3.02M), average EBITDA is $-3.84M (high $-1.811M, low $-9.057M), average net income is $-134M (high $-42.039M, low $-371M), average SG&A $14.18M (high $33.44M, low $6.69M), and average EPS is $-1.183 (high $-0.371, low $-3.273).
Did the TCRX's actual financial results beat the analysts' financial forecasts?
Based on TScan Therapeutics's last annual report (Dec 2022), the company's revenue was $13.54M, which missed the average analysts forecast of $13.79M by -1.83%. Apple's EBITDA was $-65.045M, beating the average prediction of $-8.272M by 686.31%. The company's net income was $-65.806M, missing the average estimation of $-301M by -78.17%. Apple's SG&A was $20.35M, missing the average forecast of $30.55M by -33.37%. Lastly, the company's EPS was $-2.74, missing the average prediction of $-2.894 by -5.32%. In terms of the last quarterly report (Dec 2023), TScan Therapeutics's revenue was $7.21M, beating the average analysts' forecast of $3.45M by 108.77%. The company's EBITDA was $-20.077M, beating the average prediction of $-2.072M by 868.78%. TScan Therapeutics's net income was $-19.613M, missing the average estimation of $-32.799M by -40.20%. The company's SG&A was $4.88M, missing the average forecast of $7.65M by -36.20%. Lastly, the company's EPS was $-0.21, missing the average prediction of $-0.289 by -27.38%